{"organizations": [], "uuid": "90dd1045f364abfeb338f28f449c869a8b1c8733", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-esperion-reports-qtrly-loss-per-sh/brief-esperion-reports-qtrly-loss-per-share-1-44-idUSASB0C6DB", "country": "US", "domain_rank": 408, "title": "BRIEF-Esperion Reports Qtrly Loss Per Share $1.44", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.126, "site_type": "news", "published": "2018-02-20T20:53:00.000+02:00", "replies_count": 0, "uuid": "90dd1045f364abfeb338f28f449c869a8b1c8733"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-esperion-reports-qtrly-loss-per-sh/brief-esperion-reports-qtrly-loss-per-share-1-44-idUSASB0C6DB", "ord_in_thread": 0, "title": "BRIEF-Esperion Reports Qtrly Loss Per Share $1.44", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "esperion therapeutics inc", "sentiment": "negative"}, {"name": "esperion", "sentiment": "negative"}, {"name": "dec", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Esperion Therapeutics Inc:\n* ESPERION PROVIDES BEMPEDOIC ACID FRANCHISE DEVELOPMENT PROGRAM UPDATES; REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* ESPERION THERAPEUTICS INC - EXPECTS FULL-YEAR 2018 NET CASH USED IN OPERATING ACTIVITIES TO BE APPROXIMATELY $135 TO $145 MILLION\n* ESPERION THERAPEUTICS INC - EXPECTS CASH AND CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE ABOUT $130 TO $140 MILLION AT DEC 31, 2018\n* ESPERION THERAPEUTICS INC - QTRLY LOSS PER SHARE $1.44 Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T20:53:00.000+02:00", "crawled": "2018-02-21T21:05:48.088+02:00", "highlightTitle": ""}